Literature DB >> 34750858

Childhood obesity: A review of current and future management options.

Louise J Apperley1, James Blackburn2, Karen Erlandson-Parry3, Lucy Gait4, Peter Laing1, Senthil Senniappan1.   

Abstract

Obesity is becoming increasingly prevalent in paediatric populations worldwide. In addition to increasing prevalence, the severity of obesity is also continuing to rise. Taken together, these findings demonstrate a worrying trend and highlight one of the most significant challenges to public health. Childhood obesity affects multiple organs in the body and is associated with both significant morbidity and ultimately premature mortality. The prevalence of complications associated with obesity, including dyslipidaemia, hypertension, fatty liver disease and psychosocial complications are becoming increasingly prevalent within the paediatric populations. Treatment guidelines currently focus on intervention with lifestyle and behavioural modifications, with pharmacotherapy and surgery reserved for patients who are refractory to such treatment. Research into adult obesity has established pharmacological novel therapies, which have been approved and established in clinical practice; however, the research and implementation of such therapies in paediatric populations have been lagging behind. Despite the relative lack of widespread research in comparison to the adult population, newer therapies are being trialled, which should allow a greater availability of treatment options for childhood obesity in the future. This review summarizes the current evidence for the management of obesity in terms of medical and surgical options. Both future therapeutic agents and those which cause weight loss but have an alternative indication are also included and discussed as part of the review. The review summarizes the most recent research for each intervention and demonstrates the potential efficacy and limitations of each treatment option.
© 2021 John Wiley & Sons Ltd.

Entities:  

Keywords:  BMI; childhood obesity; lifestyle interventions; paediatrics; pharmacotherapy

Mesh:

Year:  2021        PMID: 34750858     DOI: 10.1111/cen.14625

Source DB:  PubMed          Journal:  Clin Endocrinol (Oxf)        ISSN: 0300-0664            Impact factor:   3.478


  1 in total

1.  Evaluation of the promoter methylation status of hypoxia factor 3A and interleukin-6 genes and expression levels of mir-130b and mir-146b in childhood obesity.

Authors:  Esra Tekcan; Nurten Kara; Hasan Murat Aydın; Ümmet Abur; Mohsen Abbaszadeh
Journal:  Rev Assoc Med Bras (1992)       Date:  2022-09       Impact factor: 1.712

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.